A panel of outside experts advising the U.S. Food and Drug Administration voted Wednesday, Sept. 23, that the benefits of Galleri, a blood test that screens for signals from many types of cancer, outweigh its risks for adults 50 and older. The panel was more divided on the question that matters most to patients, whether the test works well enough. That vote was 6 to 4.
The panel also voted 10 to 0 that there is reasonable assurance the test is safe and 7 to 2, with one abstention, that its benefits outweigh its risks, STAT reported. The votes are recommendations only. The FDA is not bound by them and has not decided whether to approve Galleri, which is the furthest along of the multi-cancer blood tests seeking agency approval.
The split matters for patients because the test is already on the market. Galleri is available by prescription and costs $949, NPR reported. Approval could eventually open the door to insurance and Medicare coverage. For now, most people who buy the test pay out of pocket for a product whose effectiveness divided the government's own expert advisers.
Four No Votes Put the Evidence Gap on the Record
The effectiveness question asked whether there is reasonable assurance that Galleri works for its intended users: adults 50 and older, screened in addition to, not instead of, recommended tests such as mammograms and colonoscopies. Four of the 10 voting members said no.
Those concerns surfaced during the hearing. Phil Castle, director of the National Cancer Institute's Division of Cancer Prevention, told the panel the performance data were too premature to prove the test would provide clinical benefit and warned that it could give people a false sense of security. "Routine approval and broad population rollout would risk harm and waste resources," Castle said before the vote, according to NPR.
The panel recommended that Galleri's marketing materials tell people to continue routine cancer screenings and avoid describing the test as an early detection tool, NPR reported. That second recommendation goes to the core of the product's pitch, since GRAIL markets Galleri as a multi-cancer early detection test.
In the two main large clinical trials, the test often did not detect many cancers, especially early-stage ones, according to NPR. MedicalDaily's pre-vote explainer on what the Galleri evidence shows walked through those results, including the main goal the largest randomized study did not meet. The new development is that federal advisers have now formally weighed that evidence, and four of 10 were not persuaded on effectiveness.
GRAIL and the FDA Frame the Vote Differently
GRAIL welcomed the outcome. "Today's vote reinforces the strength of Galleri's clinical evidence," CEO Josh Ofman said in a company statement. The company said the FDA is expected to make a final decision in the coming months. GRAIL has a direct financial interest in approval.
Michelle Tarver, who leads the FDA's Center for Devices and Radiological Health, struck a more cautious note. She said the concept of a blood-based multi-cancer detection test "represents a genuinely promising opportunity," according to NPR.
GRAIL filed its premarket approval application in January 2026, and Galleri has held Breakthrough Device designation since 2018. The test looks for cancer-specific methylation patterns, chemical tags on DNA fragments that tumors shed into the blood, and predicts where in the body a cancer signal most likely started. The votes came from the FDA's Molecular and Clinical Genetics Panel. A positive result is not a diagnosis; it requires follow-up testing to confirm or rule out cancer.
Adults 50 and Older Face the Biggest Decision
Adults 50 and older, the only group covered by the proposed use, are the most directly affected. That includes people with a family history of cancer who may feel pressure to do everything possible, and older adults on fixed incomes for whom a $949 bill is significant.
Two risks run in opposite directions. A negative result can offer false reassurance, because the test misses many cancers. A positive result can lead to imaging, biopsies, bills, and weeks of worry, and not every positive result turns out to be cancer.
The panel's votes do not change current screening recommendations. Adults 50 and older should stay current on screenings recommended for their age and risk, including colorectal, breast and cervical cancer screening and, for eligible current or former heavy smokers, lung cancer screening.
Anyone considering Galleri can ask a clinician three practical questions: What would a positive result trigger? Would follow-up scans be covered by insurance? Do personal risk factors make the test worth the cost? New symptoms such as unexplained weight loss, persistent pain, unusual bleeding or a new lump need prompt medical attention, regardless of any blood test result.
Cost remains the biggest barrier. Congress has approved Medicare coverage for multi-cancer detection tests that win FDA approval, with reimbursement allowed starting in 2028, NPR has reported. Until the FDA acts and insurers set their policies, most patients will keep paying out of pocket.
The FDA could approve the test, reject it or approve it with conditions, including labeling limits like those the panel suggested. MedicalDaily will report the agency's final decision and any insurance or Medicare changes that follow.
An FDA panel has backed the first multi-cancer blood test to reach this stage, but a 6-to-4 effectiveness vote shows real expert doubt. Adults 50 and older who use Galleri should treat it as an add-on to proven screening, not a replacement, and should talk through the costs of a positive result before testing.
Key Questions Answered
What did the FDA panel decide?
The panel voted 10 to 0 that Galleri is reasonably safe, 6 to 4 that it is reasonably effective and 7 to 2, with one abstention, that its benefits outweigh its risks for adults 50 and older.
Is the Galleri test FDA-approved now?
No. Advisory votes are recommendations. The FDA is expected to make its final decision in the coming months.
Can people get the test today?
Yes. Galleri is available by prescription and costs $949, according to NPR. Most patients pay out of pocket.
Can Galleri replace a colonoscopy or mammogram?
No. GRAIL and the proposed use both describe it as an addition to, not a substitute for, recommended cancer screenings.
What happens if the test finds a cancer signal?
A positive result requires follow-up tests, often imaging, to confirm or rule out cancer. Not every positive result means cancer, so patients should ask about follow-up costs before testing.
Published by Medicaldaily.com
